iX Biopharma Ltd: Strategic Share Placements to Strengthen Capital and Align Key Stakeholders

Key Highlights from the Announcement

• Proposed issuance of 1,349,434 new shares: iX Biopharma plans to place 1,045,164 new ordinary shares with Anson Properties Pte. Ltd. and 304,270 new shares with three Directors in lieu of Directors’ fees.
• Placement price: Both sets of shares are to be issued at S\$0.4215 per share, reflecting the volume weighted average price (VWAP) on the Singapore Exchange as of April 16, 2026.
• Gross proceeds: The Anson Placement will raise S\$440,537 in gross proceeds, with net proceeds (after estimated expenses) of S\$398,000.
• Shareholder approval required: Both placements are subject to approval at an Extraordinary General Meeting (EGM). Relevant parties will abstain from voting.
• Strategic rationale: The placements will reinforce the capital base, conserve cash, and align Directors’ interests with shareholders.
• Financial impact: The placements will increase NAV per share and slightly reduce loss per share for FY2025.
• No change in control: The placements will not result in a transfer of controlling interest.

Details of the Proposed Placements

Anson Properties Placement

• Anson Properties Pte. Ltd., a substantial long-term shareholder (currently holding 5.99% of shares), will subscribe for 1,045,164 new shares, raising S\$440,537.
• The placement is being executed as Anson Properties was unable to participate in a recent rights issue due to timing of funds but has reaffirmed its commitment to invest equivalent capital.
• No placement agent or promotional fees incurred, only administrative/professional expenses.
• Placement falls under private placement exemption per Singapore law; no offer information statement will be issued.

Directors’ Placement

• Three Directors—Mr. Patrick Donald Davies (Lead Independent), Mr. Teo Woon Keng John (Independent), and Mr. Albert Ho Shing Tung (Non-Executive Non-Independent)—will receive shares in lieu of S\$128,250 in directors’ fees for 1 October 2025 to 31 March 2026.
• Individual allocations: Mr. Davies (106,168 shares), Mr. Teo (99,051 shares), Mr. Ho (99,051 shares).
• Purpose is to conserve cash and further align directors’ interests with shareholders and the company’s long-term outlook.
• The Board confirms this will not affect the independence of the Directors given individual shareholdings remain below 5%, and the placement is for settling existing debt (fees), not new obligations.

Financial and Shareholding Impact

• Share capital: Will increase from 1,048,324,529 to 1,049,673,963 shares.
• NAV per share: Rises from S\$0.04 to S\$0.10 after placements.
• Loss per share for FY2025: Slight reduction from (1.16) cents to (1.15) cents.
• Directors and substantial shareholders’ interests adjusted accordingly, with minor increases in shareholdings for participating Directors and Anson Properties.

Shareholder Considerations & Price Sensitive Points

• Shareholders must approve the placements at an upcoming EGM. The relevant parties will abstain from voting.
• The placements are likely to be price-sensitive given the direct infusion of capital, improved NAV per share, and alignment of Directors’ interests with shareholders.
• The new shares issued rank pari passu with existing shares except for dividends or distributions declared prior to their issuance.
• The Anson Placement reinforces the confidence of a substantial shareholder, possibly reflecting positive sentiment on the company’s strategic direction.
• No change in controlling interest, but increased institutional and director alignment may impact investor perception positively.
• The proceeds will be used entirely for working capital purposes, supporting ongoing operations and growth initiatives.
• The Directors’ Placement settles fees with equity rather than cash, preserving liquidity and underscoring Directors’ confidence in the company’s prospects.
• All necessary confirmations regarding independence, absence of concert party arrangements, and compliance with Catalist Rules have been made by both Anson Properties and the Directors.
• Shareholders can inspect relevant documents at the company’s principal place of business prior to the EGM.
• The company will make periodic announcements on the utilisation of net proceeds.

Next Steps

• A circular detailing the placements and EGM notice will be issued to shareholders in due course.
• Application for listing and quotation of the new shares will be made to SGX-ST.
• Shareholders are urged to review all information and participate in the EGM to vote on the proposed placements.

Potential Impact on Share Price

The proposed placements are likely to be price sensitive:

• They signal significant shareholder and director confidence in the company’s future.
• The improved NAV per share and capital infusion may enhance investor sentiment.
• Conservation of cash and strengthened capital base could support ongoing operations and provide flexibility for future growth.
• Shareholders’ approval process and the abstention of interested parties ensure transparency and compliance with regulations.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should review official company documents, consult their financial advisors, and consider their own investment objectives before making any decisions. The information herein is based on publicly available announcements as of the date indicated and may be subject to change. Neither the author nor this publication assumes any responsibility for decisions made based on this content.

View IX BiopharmaW260718 Historical chart here